A study in people with multiple sclerosis.

Recruiting now. Registry record last updated March 17, 2026.

Who can join: Adults 18 to 70, have multiple sclerosis, BMI 24+.
What you take: Check ClinicalTrials.gov for this trial's study groups and what each group receives.
How long it lasts: The full study runs about 3 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Not ApplicableSponsor Northwestern UniversityDrug GLP-1Class OtherSites 1 USEnrollment target 100

What this study is for

Primary condition: Multiple Sclerosis.

Full scientific study title: People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists.

Who can join

Age18 to 70SexAnyBMI24 or higher

Adults 18 to 70, have multiple sclerosis, BMI 24+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Diagnosis of MS (2019 revised McDonald criteria) of any type (PPMS, RRMS, SPMS) by a neurologist,
Adult age 18-70 years,
BMI \>=24.0 kg/m2,
Taken at least one dose of Ocrelizumab prior to study entry,
EDSS \<7.0,

Key exclusion criteria

Prior exposure to Mavenclad, Lemtrada, Cyclophosphamide, stem cell transplant or related bone marrow suppressive treatment,
Current clinical trial participant,
Unable to speak a language for which translation can be found in the hospital system,
Unclear documentation of MS diagnosis or prior or current MS treatment,
Relapse within the past 3 months,

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Illinois1 site

Northwestern Memorial Hospital
Chicago, Illinois
Dylan Rice, BA240-362-4800dylan.rice@northwestern.edu

Follow this trial

We email you if NCT07207148 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: November 15, 2025. Expected completion: August 31, 2028. Last updated on ClinicalTrials.gov: March 17, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.